Dasatinib

It is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor for use in patients with chronic myelogenous leukemia (CML).

Indications

Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) with resistance or intolerance to prior therapy.

Dosage

Oral; 100-140mg daily. Tablets need to be swallowed, not to crush or chew it.

Contra-Indications

Hypersensitivity to dasatinib.

Special Precautions

Paediatric: Safety not established. Pregnancy: Category D; risk to fetus. Lactation: Secreted in milk, can cause harm to child. Elderly: Toxicity chance increases in elderly over 65 years of age.

Side Effects

Low blood counts, bleeding, pulmonary artery hypertension, diarrhea, headache, cough, skin rash, fever, nausea, tiredness, vomiting, muscle pain, weakness, infections.

Drug Interactions

Artemether, Omeprazole, Pantoprazole, Phenobarbital, Rabeprazole, Ranitidine, Rifampin, Tacrolimus, Telithromycin, Thiothixene, Toremifene, Trimipramine, Voriconazole, Vorinostat, Ziprasidone.